

ERRATUM

SUNGMAN CHA: Tight-binding inhibitors—I. Kinetic behavior. *Biochem. Pharmac.* **24**, 2177 (1975).

The author wishes to make the following corrections in the above article:

(1) Equation 28 on p. 2181 should read:

$$k_5(I)(E) - k_6(EI) = \frac{d(EI)}{dt} = -\left(1 + \frac{K_m}{S}\right) \frac{d(ES)}{dt}$$
 (28)

(2) Table 1 on p. 2182 should read as follows:

Table 1. Comparison of different competitive and non-competitive inhibition mechanisms				
	Mechanism A	Mechanism B	Mechanism C	Mechanism D
Assumptions	$K_m \gg K_i$ $k_2 \gg k_6$ $k_1 S \gg k_5 I$	$K_m \gg K_i$ $k_2 \gg k_7$ $k_2 \gg k_8$	$K_m \gg K_i$ $k_2 \gg k_6 \gg k_5$	$K_m \gg K_i$ $k_2 \gg k_6, k_2 \gg k_8$ $k_1 S \gg k_5 I, k_1 S \gg k_7 I$
Definitions				
$K_m$	$(k_2 + k_3)/k_1$	$(k_2 + k_3)/k_1$	$(k_2 + k_3)(k_5 + k_6)/k_1 k_6$	$K_m = (k_2 + k_3)/k_1,$ $K'_m = k_{10}/k_9$
$K_i$	$k_6/k_5$	$k_6 k_8/k_5(k_7 + k_8)$	$(k_5 + k_6)k_8/k_5 k_7$	$K_{is} = k_6/k_5, K_{ii} = k_8/k_7$
$k'$	$\frac{k_6\left(1 + \frac{I}{K_i} + \frac{S}{K_m}\right)}{1 + \frac{S}{K_m}}$	$\frac{k_8\left(1 + \frac{I}{K_i} + \frac{S}{K_m}\right)}{1 + \frac{S}{K_m} + \frac{k_5 I}{k_6}}$	$\frac{k_8\left(1 + \frac{I}{K_i} + \frac{S}{K_m}\right)}{1 + \frac{S}{K_m}}$	$\frac{\left(k_5 + \frac{k_7 S}{K_m}\right)I}{1 + \frac{S}{K_m}} + \frac{k_6 + \frac{k_8 S}{K'_m}}{1 + \frac{S}{K'_m}}$
Diagnostic plots				
$k'$ vs $S'$	Hyperbola	Hyperbola	Hyperbola	Hyperbola
$k'$ vs $I$	Linear	Hyperbola	Linear	Linear

## AIMS AND SCOPE

BIOCHEMICAL PHARMACOLOGY published twice a month provides a forum for rapid publication of original research papers, short communications, preliminary communications and invited commentaries.

Research carried out with intact animals, cells, sub-cellular components, enzymes and model systems are acceptable if they define the mode of drug action. Studies concerned with antimicrobial and antiviral agents are welcomed, as well as descriptive mathematical models including those involving computer techniques. The use of drugs to elucidate physiological and behavioural mechanisms in the living organism are also acceptable.

In general, papers which record concentrations of drugs and metabolites in body fluids will not be accepted, unless they define biochemical and biophysical mechanisms; however, the Editors reserve the right to publish any papers of major interest in the field.

### 1. Original Research Papers

**2. Short Communications** which may be presented without sub-division into sections such as Introduction, Experimental, etc.

**3. Preliminary Communications** will provide a forum for the rapid dissemination of **timely and significant** observations within the Aims and Scope of the Journal on the development of biologically active substances and their mode of action at the molecular and cellular levels. Manuscripts, which may be submitted in English, French or German, will be judged as appropriate for publication as Preliminary Communications on the basis of their immediate importance and should be written as to clearly emphasize the novel aspects of the research reported. These criteria will be applied strictly.

**4. Commentaries** are short commissioned review articles (3000–5000 words in length). Two Consulting Editors will deal with these, Professor Z. M. Bacq for Europe and the Eastern Hemisphere and Professor P. A. Shore for the United States and the Western Hemisphere. Commentaries are not to be exhaustive reviews but short articles (mini-reviews) intended to stimulate thought. They can be controversial and can focus either on areas in which there is much activity or draw attention to the relatively neglected fields in which there are opportunities for research in biochemical pharmacology. Particularly welcome will be commentaries where the author gives his personal view on the state of the subject on which he is reporting and gives a view as to where in the short and medium term the subject may be moving. Authors are encouraged to take issue with popular dogmas.

## NOTES FOR CONTRIBUTORS OF FULL LENGTH PAPERS AND SHORT COMMUNICATIONS

### Submission of Contributions

Original contributions should be sent to one of the Regional Editors, whose addresses are given inside the front cover, as follows: Papers from the American continent should be sent to Professor A. C. Sartorelli, papers from continental Europe to Dr. J. Gielen, papers from the United Kingdom to Professor P. Alexander and papers from Asia, Africa or Australia to either Professor A. C. Sartorelli or Professor P. Alexander.

### Form of Contributions

Papers should be submitted in English together with an Abstract briefly summarizing the essential contents. The manuscript (including figure captions and references) should be sent in duplicate and it must be typewritten on one side of the paper with lines double-spaced and with wide margins. The form generally accepted by learned societies should be followed, with an Abstract, Introduction, Experimental section, Results, Discussion. In the case of Short Communications these sections may be combined, e.g. Experimental and Results, or Results and Discussion and there will be no abstract but a short summary at the end is required. To facilitate Abstracting, *it is the policy of the Journal to print the first full name of each author of a paper to be published in the Journal*. The original manuscript and diagrams will be discarded 1 month after publication unless the publisher is requested to return original material to the author.

### Proofs and Reprints

A reprint order form will be supplied with page proofs sent to the authors for checking. *Any corrections to proofs must be restricted to printer's errors*. Other than these, any substantial changes at this stage may be charged to the author.

### Nomenclature and Abbreviations

Where possible, nomenclature and abbreviations should be in accord with internationally agreed rules. When an enzyme or compound is first mentioned in the text, specification by its code number accompanied by its systematic name (as distinct from its trivial name) is requested by the Editors, but not checked for correctness. Official names of drugs are preferred to trade names.

The following abbreviations may be used without definition, except in titles: CoA (for coenzyme A), EDTA, Tris (for 2-amino-2-hydroxymethylpropane-1:3-diol), DNA, RNA, FAD, NAD (*not* DPN, for nicotinamide adenine dinucleotide), NADP (*not* TPN). Accepted abbreviations may be used for 5'-ribonucleotides (GMP, IDP, UTP, etc.), and for 5'-deoxyribonucleotides (dAMP, dCDP, dTTP, etc.).

Temperatures denoted by an unqualified degree symbol ° are assumed to be centigrade. For solution strengths, percentages should be expressed by the sign %, followed in cases of ambiguity by w/w, w/v, or v/v (e.g. 5%, (w/v) means 5 g/100 ml). In spectrophotometry extinction (*E*) should be used, rather than optical density.

The following sources give useful guidance on the preparation of manuscripts:

Suggestions and Instructions to Authors, *Biochem. J.* **126**, 1 (1972). It is particularly requested that authors follow the instructions on isotopically labelled compounds.

Terminology and Abbreviations, *J. biol. Chem.* **238**, 6 (1963).

*Report of the Commission on Enzymes* (I.U.B. Symposium), Pergamon Press, Oxford (1961).

*Style Manual for Biological Journals*, American Institute of Biological Sciences, 2000 P. Street, N.W. Washington 6, D.C.

### Illustrations

Illustrations for reproduction normally should be about twice the final size required. They should be separate from the typescript with captions typed together on a separate sheet. Photographs should be included only when they are essential and must be in the form of good quality glossy prints. Wherever possible, line diagrams should be in the form of good quality originals or clear photoprints from which it is possible to make direct reproductions.

### Tables

Authors are asked to keep tabular matter to a minimum. Tables should be completely intelligible without reference to the text. Each table and every column, should be provided with an explanatory heading, with units of measure clearly indicated. The same data should not be reproduced in both tables and figures.

### References

References are made by consecutive numbers in square brackets in the text, the full reference being cited in a numbered list at the end of the paper. References should contain the names and initials of *all* the authors of each paper, together with the abbreviated journal title, the volume number, first page number and the year, as follows:

1. R. Tapia, H. Pasantes, B. G. Ortega and G. H. Massieu, *Biochem. Pharmac.* **15**, 1831 (1966).
2. F. Cedrangolo, in *Chemical and Biological Aspects of Pyridoxal Catalysis* (Eds. E. E. Snell, P. M. Fasella, A. E. Braunstein and A. Rossi Fanelli) p. 343. Pergamon Press, Oxford (1963).

The titles of journals should be abbreviated in accordance with the 4th edn. *The World List of Scientific Periodicals*.

### Footnotes

Footnotes, as distinct from literature references, should be indicated by the following symbols: \*, †, ‡, § starting afresh on each page. They should not be included in the numbered reference system. Footnotes should be used for references to unpublished work, personal communications, proprietary names of trade-marked drugs and other material not appropriately referred to in the text or in the numbered reference list but should be kept to a minimum.

## INSTRUCTIONS FOR THE PREPARATION OF PRELIMINARY COMMUNICATIONS

It should be pointed out that as the typewritten manuscript is reproduced *photographically*, and each communication is a separate entity, an odd number of pages results in a blank page, which costs almost as much to produce as a full page. In general, only papers of 2 or 4 pages will be accepted.

1. Manuscripts should be typed, *double spaced*, using a black ribbon (blue ink cannot be reproduced) on good quality white bond paper. The typist should ensure a clean clear impression on the letters. A duplicate (carbon or photocopy) should accompany the original.
2. Special size paper, 28 cm (11 in.) wide by 38 cm (15 in.) deep with the exact typing area of 20 cm (7 $\frac{3}{4}$  in.) by 31 cm (12 $\frac{1}{4}$  in.), will be supplied on request.
3. Any good quality paper may be used, provided the actual typing area is 20 cm (7 $\frac{3}{4}$  in.) by 31 cm (12 $\frac{1}{4}$  in.), the margins being provided during reproduction. The title should be all in *capital letters*, centred on the width of page 1 with the title at least 5 cm (2 in.) from the top of the page. After a two-line (quadruple) space, the author's name should be typed, and after a one-line (double) space the author's address should be typed capitalizing the first letter of all main words. A three-line (sextuple) space following the author's address should be left before commencing to type the text of the article. The typing area of page 1, including the title should be 20 cm (7 $\frac{3}{4}$  in.) wide by 29 $\frac{1}{2}$  cm (11 $\frac{1}{2}$  in.) deep.
4. The typing area of *all* other pages should be extended to a depth of 31 cm (12 $\frac{1}{4}$  in.).
5. The drawing of formulae, graphs and other figures should be included in the text, so as not to exceed the specified typing area. Illustrations may be in the form of glossy prints pasted into the appropriate place or else they may be carefully drawn in black ink onto the typing area in a size that will remain legible after a slight reduction. Again ensure that the caption does not become confused with the text.
6. Each page should be numbered lightly at the bottom of the sheet in blue pencil.
7. An assurance should be given that the material has not been published or submitted elsewhere in preliminary form.

### Reprints

Owing to the short production time for Preliminary Communications, it is essential to indicate the number of reprints required *when submitting* the manuscript. However it will also be necessary to return immediately to the Publisher the reprint order form accompanying the notification of acceptance. Orders received after a particular issue has been printed will be delayed and a separate price quotation will be necessary.

**Mailing of Communications**—Preliminary Communications from the American Continent should be submitted in duplicate to Professor A. C. Sartorelli. From the European Continent, authors are advised to submit communications in duplicate to one of the special Communications Editors listed opposite. This will expedite publication. Alternatively, communications may be submitted to either Dr. J. Gielen or Professor P. Alexander. Authors from Africa, Asia, Japan, Australia and New Zealand may follow either procedure.